Can the Gene Expression Profile of Patients with Acute Myeloid Leukemia Predict Complete Remission Following...

Area of Science:

• Hematology
• Genomics
• Molecular Biology

Background:

• Personalized medicine in acute myeloid leukemia (AML) is advancing with targeted therapies like BCL2 and BET protein inhibitors.
• Standard induction chemotherapy remains the primary treatment, but identifying responders to both standard and novel therapies is crucial.
• Understanding the molecular profiles of AML patients is key to optimizing treatment strategies.

Purpose of the Study:

• To analyze the expression of key AML-related genes (BCL2, BRD4, TET2, EZH2, ASXL1, MYC) in AML patients.
• To investigate the relationship between gene expression, clinical variables, and patient outcomes at different disease stages.
• To identify potential biomarkers for treatment response and remission in AML.

Main Methods:

• Gene expression analysis of 176 AML patients at diagnosis, post-induction, complete remission, and relapse.
• Focus on genes targeted by novel therapies (BCL2, BRD4) and related epigenetic modulators (TET2, EZH2, ASXL1, MYC).
• Correlation of gene expression patterns with clinical data and treatment outcomes.

Main Results:

• Higher TET2 expression was observed post-induction (PI) and at complete remission (CR) compared to diagnosis (Dx).
• Significantly higher TET2 expression post-induction was noted in patients who achieved CR versus those who did not.
• Elevated MYC and BCL2 expression levels were associated with potential vulnerability to BRD4 inhibition.

Conclusions:

• Upregulation of TET2 post-induction may serve as a predictive marker for achieving complete remission in AML.
• Identifying patients with high MYC and BCL2 expression could guide the use of BRD4 inhibitors for targeted therapy.
• These findings contribute to a deeper understanding of AML molecular heterogeneity and personalized treatment approaches.